Wang, J., Liu, S. V., Uronis, H. E., Wu, C., Mahalingam, D., Spira, A., … Kelly, K. (2018). Novel small-molecule RORγ agonist immuno-oncology agent LYC-55716: Safety and efficacy in a phase IIA open-label, multicenter trial. In Ann Oncol (Vol. 29 Suppl 8, pp. viii404–viii405). England. https://doi.org/10.1093/annonc/mdy288.012

Wang, J., S. V. Liu, H. E. Uronis, C. Wu, D. Mahalingam, A. Spira, L. Carter, et al. “Novel small-molecule RORγ agonist immuno-oncology agent LYC-55716: Safety and efficacy in a phase IIA open-label, multicenter trial.” In Ann Oncol, 29 Suppl 8:viii404–5, 2018. https://doi.org/10.1093/annonc/mdy288.012.

Wang J, Liu SV, Uronis HE, Wu C, Mahalingam D, Spira A, et al. Novel small-molecule RORγ agonist immuno-oncology agent LYC-55716: Safety and efficacy in a phase IIA open-label, multicenter trial. In: Ann Oncol. 2018. p. viii404–5.

Wang, J., et al. “Novel small-molecule RORγ agonist immuno-oncology agent LYC-55716: Safety and efficacy in a phase IIA open-label, multicenter trial.” Ann Oncol, vol. 29 Suppl 8, 2018, pp. viii404–05. Pubmed, doi:10.1093/annonc/mdy288.012.

Wang J, Liu SV, Uronis HE, Wu C, Mahalingam D, Spira A, Carter L, Hu X, Weems G, Wilkins HJ, Duska LR, Kelly K. Novel small-molecule RORγ agonist immuno-oncology agent LYC-55716: Safety and efficacy in a phase IIA open-label, multicenter trial. Ann Oncol. 2018. p. viii404–viii405.